ARDELYX, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ARDELYX, INC. (ARDX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $11.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-19
- ARDELYX, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $11.00M, a 11.29% decline from fiscal 2024.
- ARDELYX, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $12.40M, a 39.51% decline from fiscal 2023.
- ARDELYX, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $20.50M, a 0.00% change from fiscal 2022.
- ARDELYX, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $20.50M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $11.00M 10-K · filed 2026-02-19 |
| 2024-12-31 | $12.40M 10-K · filed 2025-02-20 |
| 2023-12-31 | $20.50M 10-K · filed 2024-02-22 |
| 2022-12-31 | $20.50M 10-K · filed 2023-03-02 |
| 2018-12-31 | $19.70M 10-K · filed 2019-03-06 |
| 2017-12-31 | -$12.60M 10-K · filed 2019-03-06 |
| 2016-12-31 | $40.70M 10-K · filed 2019-03-06 |
| 2015-12-31 | $9.10M 10-K · filed 2018-03-14 |
| 2014-12-31 | -$300.00K 10-K · filed 2016-03-04 |
| 2013-12-31 | $1.50M 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |